Background BK-SE36/CpG is a recombinant blood-stage malaria vaccine candidate based
on the N-terminal Plasmodium falciparum serine repeat antigen5 (SE36), adsorbed to …

Background Up to now a malaria vaccine remains elusive. The Plasmodium falciparum
serine repeat antigen-5 formulated with aluminum hydroxyl gel (BK-SE36) is a blood-stage …

Background BK-SE36 is blood-stage malaria vaccine candidate that is undergoing clinical
trials. Here, the safety and immunogenicity of BK-SE36 with a novel adjuvant, CpG-ODN …

The malaria vaccine BK-SE36 is a recombinant protein (SE36) based on the Honduras 1
serine repeat antigen-5 of Plasmodium falciparum, adsorbed to aluminium hydroxide gel …

Background A vaccine targeting the erythrocyte stages of Plasmodium falciparum could play
a role in preventing clinical disease. BK-SE36 is a promising malaria vaccine candidate that …

Background A blood-stage vaccine targeting the erythrocytic-stages of the malaria parasite
Plasmodium falciparum could play a role to protect against clinical disease. Antibodies …

The malaria vaccine candidate antigen, SE36, is based on the N-terminal 47 kDa domain of
Plasmodium falciparum serine repeat antigen 5 (SERA5). In epidemiological studies, we …

The SE36 antigen, derived from serine repeat antigen 5 (SERA5) of Plasmodium falciparum,
is a promising blood stage malaria vaccine candidate. Ongoing clinical trials suggest the …

BACKGROUND Malaria transmission-blocking vaccines aim to interrupt the transmission of
malaria from one person to another. METHODS The candidates R0. 6C and ProC6C share …

Malaria transmission is in decline in some parts of Africa, partly due to the scaling up of
control measures. If the goal of elimination is to be achieved, additional control measures …